News
Phase 2 colorectal cancer trial opens at Guangdong Provincial People’s Hospital
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A phase 2 study registered on ClinicalTrials.gov and last updated on 24 September 2026 is recruiting about 160 patients with refractory RAS wild-type metastatic colorectal cancer. The record names Guangdong Provincial People’s Hospital in Guangzhou as the sponsor and site and lists bevacizumab, sintilimab, cetuximab and irinotecan; the stated primary endpoint is objective response rate. Registry entries describe studies; they are not recommendations.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open access / public domain; summary and link published here, the original remains authoritative.